Program Description
Asparaginase therapy remains a critical component of treatment for acute lymphoblastic leukemia (ALL) across pediatric, adolescent and young adult (AYA), and adult populations, yet its optimal use continues to present significant clinical challenges. Sustained asparagine depletion is essential for achieving remission and improved survival outcomes; however, premature discontinuation of therapy due to misclassified reactions can compromise treatment efficacy. Oncology pharmacists play a vital role in differentiating reaction types based on timing, symptom patterns, and clinical presentation, yet inconsistent grading and monitoring practices can hinder appropriate decision making. While therapeutic drug monitoring (TDM) offers an evidence-based strategy to distinguish immune-mediated inactivation from other reactions and guide treatment decisions, its implementation in adult and AYA ALL remains inconsistent. This case-based panel discussion will explore practical approaches for differentiating asparaginase-related reactions, optimizing exposure through TDM, and ensuring effective formulation transitions to maintain treatment continuity across pediatric, AYA, and adult populations. Faculty will review real-world cases highlighting hypersensitivity management, toxicity mitigation, and the integration or switch of asparaginase formulations. Through expert commentary and interactive discussion, participants will gain tools to apply evidence-informed strategies for individualized therapy, reduce unnecessary treatment interruptions, and contribute to consistent, high-quality asparaginase use in adult and AYA ALL care.
Target audience: Oncology pharmacistsType of activity: Application
Release date: May 18, 2026
Expiration date: May 18, 2027
Learner level: Advanced
Time to complete activity: 1.25 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Differentiate between immunologic hypersensitivity reactions from ammonia-mediated and cytokine-type infusion reactions using clinical presentation, timing, and mechanistic features
- Break down therapeutic drug monitoring results to guide patient-specific decisions regarding continuation, dose modification, or formulation switching
- Factor patient-specific factors into evidence-based decisions regarding formulation selection and toxicity management in the care of adolescents and young adults with acute lymphoblastic leukemia
- Apply evidence-informed criteria to guide appropriate formulation transitions while minimizing unnecessary patient burden and preserving therapeutic intent
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here